What Will Be Your Next Move in the In Vitro Diagnostic Space?

When it comes to in vitro diagnostic (IVD) technologies, medical device and diagnostic companies have been chomping at the bit to produce the next big innovation. The last few years have seen a surge in IVD technologies in the market, as device makers expand their knowledge and resources surrounding IVD technologies. With new products in the marketplace for direct-to-consumer tests (DTC), point-of-care diagnostics, and next-generation sequencing, we may be on the threshold of a new wave of diagnostic technologies that could have an impact on other diagnostic areas as well, such as gene sequencing and editing. These new IVD technologies could potentially be the key that unlocks the door for a whole new generation of diagnostic possibilities. In an effort to explore some of the latest IVD technologies, as well as the trends that paved the way for them, MD+DI spoke with Bill Harries, chief scientist at Aromyx, a medical technology company that focuses on capturing human olfactory and taste receptors on a disposable biochip for different therapeutic applications. Harries earned his PhD in human anatomy and cell biology from Wayne State University School of Medicine and has spent the last 30 years researching integral membrane proteins in an effort to help design, express, and incorporate the human olfactory and taste receptors into a scalable sensor platform. He’ll also be part of a panel discussion at the BIOMEDevice San Jose...
Source: MDDI - Category: Medical Devices Authors: Tags: BIOMEDevice San Jose IVD Source Type: news